Alcon Laboratories entered into a definitive agreement to acquire Zurich-based ESBATech AG in a US$589 M deal.  The eye-care leader hopes to capitalize on the latter’s antibody fragment technology platform to go beyond its traditional small molecule-based ophthalmic research and enter into biotech.